Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy

Human Gene Therapy

Volumn 28, Issue 4, 2017, Pages 328-337

  Ertl, Hildegund C J ^a   High, Katherine A ^b  

^a WISTAR INSTITUTE   (United States)

^b Ophthalmology   (United States)

Author keywords

adeno associated virus vector; dose response; gene transfer; immune response; immune suppression

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; IMMUNOSUPPRESSIVE AGENT; CAPSID PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; GENE REPLACEMENT THERAPY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; OUTCOME ASSESSMENT; PATHOGENICITY; SEROTYPE; T LYMPHOCYTE; TRANSGENE; TROPISM; VIRAL GENE DELIVERY SYSTEM; ADVERSE EFFECTS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGY; THERAPEUTIC USE;

CAPSID PROTEINS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; T-LYMPHOCYTES;

EID: 85018411347     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.172     Document Type: Article

References (102)

1. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995;2:357-362.
2. Walter J, High KA. Gene therapy for the hemophilias. Adv Vet Med 1997;40:119-134.
3. Liu YL,Mingozzi F, Rodriguéz-Colôn SM, et al. Therapeutic levels of factor IX expression using a musclespecific promoter and adeno-associated virus serotype 1 vector. Hum Gene Ther 2004;15:783-792.
4. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997;3:306-312.
5. Niemeyer GP, Herzog RW, Mount J, et al. Longterm correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009;113:797-806.
6. Marcos-Contreras OA, Smith SM, Bellinger DA, et al. Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII. Blood 2016;127:565-571.
7. Gao GP, Lu Y, Sun X, Johnston J, et al. Highlevel transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J Virol 2006;80:6192-6194.
8. Wang L, Bell P, Lin J, et al. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol Ther 2011;19:2012-2020.
9. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
10. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 2016;388:661-672.
11. Pierce EA, Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med 2015;5:a017285.
12. Leone P, Janson CG, Bilaniuk L, et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 2000; 48:27-38.
13. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson's disease: an open label, Phase I trial. Lancet 2007;369:2097-2105.
14. Vendomele JM, Khebizi Q, Mormin M, et al. Anti-transgene cellular immune responses can be induced by subretinal gene transfer with rAAV in a dose-dependent manner. ASCGT meeting 2016 Session Immunological Aspects of Gene Therapy II: AAV Vectors, Abstract 694.
15. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) Tcell responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-422.
16. George LA, Sullivan S, Teitel J, et al. Preliminary results of a Phase 1/2 trial of SPK-9001, a hyperactive FIX variant delivered by a novel capsid, demonstrate consistent factor IX activity levels at the lowest dose cohort. WHF 2016, Late-Breaking Abstract. Haemophilia 2016;22:151-152.
17. Dutta SK. Isolation and characterization of an adenovirus and isolation of its adenovirusassociated virus in cell culture from foals with respiratory tract disease. Am J Vet Res 1975; 36:247-250.
18. Grossman Z, Mendelson E, Brok-Simoni F, et al. Detection of adeno-associated virus type 2 in human peripheral blood cells. Gen Virol 1992; 73:961-966.
19. Walz CM, Anisi TR, Schlehofer JR, et al. Detection of infectious adeno-associated virus particles in human cervical biopsies. Virology 1998;247:97-105.
20. Chen CL, Jensen RL, Schnepp BC, et al. Molecular characterization of adeno-associated viruses infecting children. J Virol 2005;79:14781-14792.
21. Gao G, Alvira MR, Somanathan S, et al. Adenoassociated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A 2003;100:6081-6086.
22. Lochrie MA, Tatsuno GP, Arbetman AE, et al. Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. Virology 2006;353:68-82.
23. Dutheil N, Yoon-Robarts M, Ward P, et al. Characterization of the mouse adeno-associated virus AAVS1 ortholog. J Virol 2004;78:8917-8921.
24. Parzych EM, Li H, Yin X, et al. Effects of immunosuppression on circulating adeno-associated virus capsid-specific T cells in humans. Hum Gene Ther 2013;24:431-442.
25. Vandamme C, Devaux M, Jaulin N, et al. Phenotypic and functional characterisation of human anti-AAV CD8+ T cells using MHC class I tetramer-associated magnetic enrichment. ASCGT meeting, 2016, Session Immunological Aspects of Gene Therapy II: AAV Vectors 697.
26. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199:381-390.
27. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010;21:704-712.
28. Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015;47: 1187-1193.
29. Gil-Farina I, Fronza R, Kaeppel C, et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther 2016;24:1100-1105.
30. Nault JC, Mami I, La Bella T, et al. Wild-type AAV insertions in hepatocellular carcinoma do not inform debate over genotoxicity risk of vectorized AAV. Mol Ther 2016;24:660-661.
31. Schmidt M, Gil-Farina I, Büning H. Reply to "Wild-type AAV insertions in hepatocellular carcinoma do not inform debate over genotoxicity risk of vectorized AAV." Mol Ther 2016; 24:661-662.
32. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996;70:3235-3241.
33. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995;17:237-245.
34. Nakai H, Montini E, Fuess S, et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 2003;34:297-302.
35. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-317.
36. Srivastava A. In vivo tissue-tropism of adenoassociated viral vectors. Curr Opin Virol 2016; 21:75-80.
37. Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008;16:1073-1080.
38. Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 2014;506:382-386.
39. Vercauteren K, Hoffman BE, Zolotukhin I, et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther 2016;24:1042-1049.
40. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adenoassociated viruses. J Virol 2008;82:5887-5911.
41. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008;105:7827-7832.
42. Martini SV, Silva AL, Ferreira D, et al. Tyrosine mutation in AAV9 capsid improves gene transfer to the mouse lung. Cell Physiol Biochem 2016; 39:544-553.
43. Faust SM, Bell P, Cutler BJ, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 2013;123:2994-3001.
44. McCarty DM, Monahan PE, Samulski RJ. Selfcomplementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8:1248-1254.
45. Nathwani AC, Gray JT, Ng CY, et al. Selfcomplementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006;10:2653-2661.
46. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009;119:2388-2398.
47. Rogers GL, Suzuki M, Zolotukhin I, et al. Unique roles of TLR9-and MyD88-dependent and-independent pathways in adaptive immune responses to AAV-mediated gene transfer. J Innate Immun 2015;7:302-314.
48. Rogers GL, Martino AT, Aslanidi GV, et al. Innate immune responses to AAV vectors. Front Microbiol 2011;2:194.
49. Hösel M, Broxtermann M, Janicki H, et al. Tolllike receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 2012;55:287-297.
50. Murphy SL, Li H, Zhou S, et al. Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol Ther 2008;16:138-145.
51. Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 2013;5: 194ra92.
52. Sabatino DE, Mingozzi F, Hui DJ, et al. Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 2005;12:1023-1033.
53. Hui DJ, Edmonson SC, Podsakoff GM, et al. AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Mol Ther Methods Clin Dev 2015;2:15029.
54. Li H, Lasaro MO, Jia B, et al. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol Ther 2011;19: 2021-2030.
55. Roy S, Vandenberghe LH, Kryazhimskiy S, et al. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog 2009;5: e1000503.
56. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-499.
57. Sondhi D, Johnson L, Purpura K, et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods 2012;23:324-335.
58. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a Phase I study for Canavan disease. J Gene Med 2006;8:577-588.
59. Worgall S, Sondhi D, Hackett NR, et al Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19:463-474.
60. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371:1994-2004.
61. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adenoassociated viral vector expressing a1-antitrypsin: interim results. Hum Gene Ther 2011;22:1239-1247.
62. Li H, Murphy SL, Giles-Davis W, et al. Preexisting AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 2007;15:792-800.
63. Li H, Lin SW, Giles-Davis W, et al. A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol Ther 2009;17:1215-1224.
64. Li H, Tuyishime S, Wu TL, et al. Adenoassociated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. Mol Ther 2011;19:536-546.
65. Li C, Hirsch M, Asokan A, et al. Adenoassociated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vectortransduced cells coexpressing the AAV2 capsid in vivo. J Virol 2007;81:7540-7547.
66. Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 2013;121: 2224-2233.
67. Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006;12:967-971.
68. Hauck B, Murphy SL, Smith PH, et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther 2009;17:144-152.
69. Sykulev Y, Joo M, Vturina I, et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996;4:565-571.
70. Blander JM. The comings and goings of MHC class I molecules herald a new dawn in crosspresentation. Immunol Rev 2016;272:65-79.
71. Wang L, Figueredo J, Calcedo R, et al. Crosspresentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther 2007;18:185-194.
72. Li C, He Y, Nicolson S, Hirsch M, et al. Adenoassociated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest 2013;123:1390-1401.
73. Li C, Goudy K, Hirsch M, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A 2009; 106:10770-10774.
74. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358: 2231-2239.
75. Maguire AM, High KA, Auricchio A, et al. Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a Phase 1 doseescalation trial. Lancet 2009;374:1597-1605.
76. Cereso N, Pequignot MO, Robert L, et al. Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient. Mol Ther Methods Clin Dev 2014;1:14011.
77. Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000;97:3428-3432.
78. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008;70:1980-1983.
79. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10:309-319.
80. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 2009;106: 16363-16368.
81. Mueller C, Chulay JD, Trapnell BC, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest. 2013;123:5310-5318.
82. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984;38: 287-292.
83. Nennesmo I, Olsson T, Ljungdahl A, et al. Interferon-gamma-like immunoreactivity and T-cell marker expression in rat skeletal muscle fibres. Brain Res 1989;504:306-310.
84. Wiendl H, Mitsdoerffer M, Schneider D, et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 2003; 17:1892-1894.
85. Lewis EC, Mizrahi M, Toledano M, et al. Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A 2008;105:16236-16241.
86. Lewis EC, Shapiro L, Bowers OJ, et al. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci U S A 2005; 102:12153-12158.
87. Shahaf G, Moser H, Ozeri E, et al. a-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol Med 2011;171000-171011.
88. Mittag A, Tarnok A. Recent advances in cytometry applications: preclinical, clinical, and cell biology. Methods Cell Biol 2011;103:1-20.
89. Leipold MD, Newell EW, Maecker HT, et al. Phenotyping of human PBMCs using mass cytometry. Methods Mol Biol 2015;1343:81-95.
90. Hewitt FC, Li C, Gray SJ, et al. Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors. J Virol 2009; 83:3919-3929.
91. Halbert CL, Miller AD, Mcnamara S, et al. 2006. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther 2006;17:440-447.
92. D'Avola D, López-Franco E, Sangro B, et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol 2016;65:776-783.
93. Miesbach W, Klamroth R, Schutgens R, et al. Updated results from a dose escalating study in adult patients with haemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy. WHF 2016, Late-Breaking Abstract. Haemophilia 2016;22: 151-152.
94. Pasi J, Rangarajan S, Pierce G, et al. Interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII gene transfer in severe hemophilia A, WHF 2016, Late-Breaking Abstract. Haemophilia 2016;22:151-152.
95. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vectormediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
96. Ferreira V, Twisk J, Kwikkers K, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a Phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 2014;25:180-188.
97. Monahan P, Walsh CE, Powell JS, et al. Update on a Phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. International Society on Thrombosis and Haemostasis 2015 Congress, June 24, 2015, Toronto, Canada, Abstract #LB101.
98. Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 2015;125: 1553-1561.
99. Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 2009;17:1888-1896.
100. Urabe M, Nakakura T, Xin KQ, et al. Scalable generation of high-titer recombinant adenoassociated virus type 5 in insect cells. J Virol 2006;80:1874-1885.
101. Venkatakrishnan B, Yarbrough J, Domsic J, et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol 2013;87:4974-4984.
102. Mietzsch M, Casteleyn V, Weger S, et al. One-Bac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum Gene Ther 2015;26:688-697.